GlassScriptPhysician profile
Jules A Cohen
NPI 1215112289
$556,986.13
in general payments reported to CMS, 2019-2025
14 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124K · 2020: $11K · 2021: $4,910 · 2022: $72K · 2023: $99K · 2024: $103K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $230K · Consulting Fee: $58K · Travel and Lodging: $47K · Food and Beverage: $6,222 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,090.00 |
| Consulting Fee | $58,199.17 |
| Travel and Lodging | $46,596.40 |
| Food and Beverage | $6,221.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,410.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149,720.77 | 2019-2025 | Kisqali |
| Gilead Sciences, INC. | $132,208.59 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $130,782.63 | 2022-2025 | Lynparza, Enhertu, Datroway |
| Stemline Therapeutics INC. | $93,149.18 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $50,343.95 | 2020-2025 | Enhertu, Datroway |
| Beigene, LTD. | $516.67 | 2025 | |
| Caris Mpi, INC. | $131.52 | 2025 | Mi Cancer Seek |
| Genentech, INC. | $75.00 | 2023 | |
| Tersera Therapeutics LLC | $40.17 | 2024-2025 | Zoladex |
| Genentech USA, INC. | $17.65 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.